Aburahma A F, Malik F S, Boland J P
Department of Surgery, West Virginia University Health Sciences Center/Charleston.
W V Med J. 1992 Mar;88(3):95-100.
Heparin-induced thrombocytopenia with thrombotic complications is a serious clinical problem. The diagnosis is confirmed by a positive heparin-induced platelet aggregation test and/or detection of white clots upon pathological exam after a presumptive diagnosis based on these criteria: (1) Development of thrombocytopenia of less than 100,000 mm3 while receiving heparin therapy; (2) Normalization of the platelet count after an interruption in heparin therapy; (3) The presence of thrombotic complications; and (4) Exclusion of other causes of thrombocytopenia. Eight patients with heparin-induced thrombocytopenia were encountered at the Charleston Area Medical Center, Memorial Division, in a recent 20-month period. Various types of heparin, routes of administration, and indications were implicated. The mean platelet nadir was 25,750 mm3 and the mean time to onset of of heparin-induced thrombocytopenia was 4.9 days. Thrombotic complications included seven patients with arterial occlusions of the legs, six with deep-vein thrombosis of the legs (three had pulmonary embolism), and five with combined arterial and venous thrombosis. Treatment strategies included discontinuation of heparin in all patients; intravenous infusion of dextran in five patients, followed by arterial thrombectomy in three patients; urokinase therapy in two patients for arterial thrombotic complications; and insertion of Greenfield filters in four patients for venous thrombotic complications. All surviving patients were given warfarin. The mortality rate was 25 percent and the morbidity rate was 38 percent. In conclusion, an initial platelet count should be obtained on all patients prior to receiving heparin, followed by repeat platelet counts every two to three days. Once thrombocytopenia or thrombosis is diagnosed, heparin should be discontinued and other therapeutic modalities considered.
肝素诱导的血小板减少症伴血栓形成并发症是一个严重的临床问题。在基于以下标准做出初步诊断后,通过肝素诱导的血小板聚集试验阳性和/或病理检查发现白色血栓来确诊:(1)接受肝素治疗时血小板计数低于100,000/mm³;(2)肝素治疗中断后血小板计数恢复正常;(3)存在血栓形成并发症;(4)排除其他导致血小板减少的原因。在最近20个月期间,查尔斯顿地区医疗中心纪念分院共遇到8例肝素诱导的血小板减少症患者。涉及多种类型的肝素、给药途径和适应证。血小板计数最低点的平均值为25,750/mm³,肝素诱导的血小板减少症的平均发病时间为4.9天。血栓形成并发症包括7例腿部动脉闭塞患者、6例腿部深静脉血栓形成患者(3例有肺栓塞)以及5例动脉和静脉联合血栓形成患者。治疗策略包括所有患者停用肝素;5例患者静脉输注右旋糖酐,其中3例随后进行动脉血栓切除术;2例患者因动脉血栓形成并发症接受尿激酶治疗;4例患者因静脉血栓形成并发症植入格林菲尔德滤器。所有存活患者均接受华法林治疗。死亡率为25%,发病率为38%。总之,所有接受肝素治疗的患者在治疗前应进行初始血小板计数,随后每两到三天重复进行血小板计数。一旦诊断出血小板减少症或血栓形成,应停用肝素并考虑其他治疗方式。